Meiji Holdings Co Ltd Ord (MEJHF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

I am Matsudaira CEO. Thank you very much for taking the time to join us today despite your busy schedule. I would also like to take this opportunity to express my sincere gratitude for your continued support. Today, I will begin by providing an overall summary. After that, CFO Hishinuma will explain the results for the first half and the outlook for the second half and the full year based on actual figures. First, regarding the summary of the first half, as already announced, consolidated offering profit reached 40.9 billion yen, exceeding the planned 39.5 billion yen. In particular, pharmaceuticals significantly exceeded the plan. And although food products fell just slightly short, overall we view the results as solid. As you know, while domestic consumption has been slow to recover, we implemented price increase for many products in the first half as well. Although we were concerned about the impact on volume, we were able to minimize the decline, at least for major products, by leveraging our past experience. Based on the results of the first half and the current business environment, we made a slight downward revision to the full-year sales forecast, but kept the operating profit forecast unchanged. In the food segment, we expect growth driven by the new products such as hemoglobin A1C, countermeasure yogurt, the relaunch of Namanotoki series, and enhanced offerings in nutrition category. In pharmaceuticals, full-scale expansion of the insomnia treatment drug will begin. Along with these initiatives, we will thoroughly manage costs to achieve full year plan. Our company-wide structural reforms have just begun, but we made several decisions and executed actions in the first half, including the termination of production at Shikoku Meiji and the implementation of t...